Gene · 862
Papers4,591
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
621 to 640 of 4,591
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The presence of Auer rods in neutrophils and monocytes besides blasts in a case of acute myeloid leukemia with CSF3R mutation. | EJHaem | 2022 | 36051019 | PubTator, text mining | PubMed |
| Whole-transcriptome bioinformatics revealed HTRA3, KRT8, KRT17, and RHEX as novel targets in acute myeloid leukaemia. | J Taibah Univ Med Sci | 2022 | 36050959 | PubTator, text mining | PubMed |
| Production of human entorhinal stellate cell-like cells by forward programming shows an important role of Foxp1 in reprogramming. | Front Cell Dev Biol | 2022 | 36046338 | PubTator, text mining | PubMed |
| Small but strong: Pivotal roles and potential applications of snoRNAs in hematopoietic malignancies. | Front Oncol | 2022 | 36033520 | PubTator, text mining | PubMed |
| Cyclin-dependent kinase inhibitors in malignant hematopoiesis. | Front Oncol | 2022 | 36033505 | PubTator, text mining | PubMed |
| Bioethanol Conversion into Propylene over Various Zeolite Catalysts: Reaction Optimization and Catalyst Deactivation. | Nanomaterials (Basel) | 2022 | 36014611 | PubTator, text mining | PubMed |
Identification of Leukemia-Associated Immunophenotypes by Databaseguided Flow Cytometry Provides a Highly Sensitive and Reproducible Strategy for the Study of Measurable Residual Disease in Acute Myeloblastic Leukemia. | Cancers (Basel) | 2022 | 36011002 | PubTator, text mining | PubMed |
| Revealing the intratumoral heterogeneity of non-DS acute megakaryoblastic leukemia in single-cell resolution. | Front Oncol | 2022 | 36003795 | PubTator, text mining | PubMed |
| Inhibitor of DNA binding proteins revealed as orchestrators of steady state, stress and malignant hematopoiesis. | Front Immunol | 2022 | 35990659 | PubTator, text mining | PubMed |
| Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia. | Mol Cancer | 2022 | 35986270 | PubTator, text mining | PubMed |
| Biophysical and pharmacokinetic characterization of a small-molecule inhibitor of RUNX1/ETO tetramerization with anti-leukemic effects. | Sci Rep | 2022 | 35986043 | PubTator, text mining | PubMed |
| Expression level and prognostic potential of beta-catenin-interacting protein in acute myeloid leukemia. | Medicine (Baltimore) | 2022 | 35984200 | PubTator, text mining | PubMed |
| Flow Cytometric DNA Ploidy Analysis in Haemato-Lymphoid Neoplasms: An Analysis of 132 Cases. | Int J Hematol Oncol Stem Cell Res | 2022 | 35975117 | PubTator, text mining | PubMed |
| Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia. | Blood Cancer J | 2022 | 35973983 | PubTator, text mining | PubMed |
| Comprehensive genomic profiling of Finnish lung adenocarcinoma cohort reveals high clinical actionability and SMARCA4 altered tumors with variable histology and poor prognosis. | Neoplasia | 2022 | 35964518 | PubTator, text mining | PubMed |
| MiR-210-3p accelerates tumor-relevant cell functions of endometrial carcinoma by repressing RUNX1T1. | Mutat Res | 2022 | 35963185 | PubTator, text mining | PubMed |
| Integration of CD34+CD117dim population signature improves the prognosis prediction of acute myeloid leukemia. | J Transl Med | 2022 | 35962395 | PubTator, text mining | PubMed |
| Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine. | Blood Cancer Discov | 2022 | 35960210 | PubTator, text mining | PubMed |
| Pan-cancer Landscape of the RUNX Protein Family Reveals their Potential as Carcinogenic Biomarkers and the Mechanisms Underlying their Action. | J Transl Int Med | 2022 | 35959452 | PubTator, text mining | PubMed |
| Single-cell analysis of transcription factor regulatory networks reveals molecular basis for subtype-specific dysregulation in acute myeloid leukemia. | Blood Sci | 2022 | 35957668 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/862/papers?page=32